Fosamax (Alendronate) EMA vs FDA Regulatory Approach: Approval History, Label Differences, and Post-Market Safety

FDA Approval History and Label Evolution

The FDA granted alendronate its first approval on September 29, 1995, under NDA 020560 for the treatment of osteoporosis in postmenopausal women. Merck marketed the drug as Fosamax. The approval leaned heavily on the Fracture Intervention Trial (FIT), a landmark randomized controlled study that enrolled 2,027 women aged 55 to 81 with at least one vertebral fracture at baseline [1].

The FIT Trial: Backbone of the Original Approval

FIT demonstrated that alendronate 5 mg/day (increased to 10 mg after two years) reduced the risk of new vertebral fractures by 47% over three years (relative risk 0.53, 95% CI 0.41 to 0.68) [1]. Hip fracture incidence dropped by 51% (RR 0.49, 95% CI 0.23 to 0.99). These results gave the FDA sufficient evidence of clinically meaningful fracture reduction across multiple skeletal sites.

Indication Expansions

The FDA expanded the label several times after 1995. A 1997 supplement added prevention of osteoporosis in postmenopausal women. By 1999, alendronate carried indications for glucocorticoid-induced osteoporosis and osteoporosis in men. The once-weekly 70 mg formulation, approved in 2000, changed prescribing practice substantially by improving adherence. A 2005 approval added a 70 mg tablet with 2,800 IU of vitamin D3 (Fosamax Plus D).

Current FDA Label Structure

The FDA label follows the Physician Labeling Rule (PLR) format, organized into 17 numbered sections. Section 5 (Warnings and Precautions) contains subsections on upper gastrointestinal adverse reactions, mineral metabolism (hypocalcemia must be corrected before starting therapy), musculoskeletal pain, osteonecrosis of the jaw, and atypical subtrochanteric and diaphyseal femoral fractures. The FDA label provides specific language instructing patients to take alendronate first thing in the morning with 6 to 8 ounces of plain water, remaining upright for at least 30 minutes [2].

EMA Regulatory Pathway and Labeling

The EMA's relationship with alendronate is more fragmented than the FDA's. Alendronate was initially authorized through national procedures in individual EU member states during the mid-1990s, with the first national marketing authorizations predating the EMA's centralized procedure for this class of drug.

Decentralised vs Centralised Authorisation

Alendronate never went through the EMA centralized procedure. Instead, it was authorized via the Mutual Recognition Procedure (MRP) and later the Decentralised Procedure (DCP). This means each member state issued its own marketing authorisation, using a reference member state's assessment. The practical consequence: minor label differences persist between EU countries, even for the same molecule at the same dose.

Summary of Product Characteristics (SmPC) vs FDA Label

The EMA-harmonized SmPC uses a different organizational scheme from the FDA's PLR format. Section 4.4 (Special Warnings and Precautions for Use) covers similar ground to FDA Section 5, but the SmPC tends to include more granular pharmacovigilance data inline. The SmPC explicitly references reports from the EudraVigilance database in its safety narrative, while the FDA label references its own Adverse Event Reporting System (FAERS). The SmPC also includes a "Date of first authorisation/Date of renewal of the authorisation" field, creating a clearer audit trail for when specific safety language was added.

Dosing and Administration Differences

Both regulators approve the same core doses (10 mg daily, 70 mg weekly for treatment). The EMA SmPC, however, is more explicit about the 5 mg daily dose for glucocorticoid-induced osteoporosis in premenopausal women receiving glucocorticoids, whereas the FDA label groups glucocorticoid-induced osteoporosis without the same premenopausal subgroup specificity [3].

Atypical Femoral Fractures: A Case Study in Divergent Timelines

The atypical femoral fracture (AFF) signal is the clearest example of how the two agencies moved at different speeds on the same safety concern.

FDA Response (2010)

The FDA issued a safety communication on October 13, 2010, requiring label changes for all bisphosphonates, including alendronate. The agency cited data from its own review of case reports submitted to FAERS and published epidemiological studies. The FDA required the addition of AFF language to the Warnings and Precautions section and specified that prescribers should periodically re-evaluate the need for continued bisphosphonate therapy, particularly after five or more years of use [4].

A 2010 task force report from the American Society for Bone and Mineral Research (ASBMR) defined the major and minor features of AFF, giving both regulators a shared case definition. The estimated incidence was 3.2 to 50 cases per 100,000 person-years of bisphosphonate use, depending on the study population and case definition [5].

EMA Response (2011)

The EMA's Pharmacovigilance Working Party completed its review of bisphosphonates and atypical femoral fractures in 2011, roughly one year after the FDA. The Committee for Medicinal Products for Human Use (CHMP) recommended that all bisphosphonate SmPCs in the EU include warnings about AFF, with language noting that these fractures may occur with minimal or no trauma in the subtrochanteric and diaphyseal regions of the femur. The EMA review drew on EudraVigilance reports and the same published literature that informed the FDA decision. The one-year lag reflects the multi-step CHMP referral process, which requires formal triggers and committee-level deliberation before label changes propagate across 27 member states.

Drug Holiday Guidance: Regulator Comparison

Neither regulator has issued a formal mandatory drug holiday protocol, but both acknowledge the concept. The FDA's 2022 updated guidance references the FLEX extension of the FIT trial, which showed that women who discontinued alendronate after five years maintained bone density gains at the hip for up to five additional years [6]. The EMA SmPC notes that the optimal duration of bisphosphonate treatment has not been established and that the need for continued treatment should be re-evaluated periodically. The American Association of Clinical Endocrinology (AACE) 2020 guidelines recommend considering a bisphosphonate holiday after five years (oral) or three years (IV zoledronic acid) in patients who are not at high fracture risk [7].

Osteonecrosis of the Jaw: Parallel but Distinct Warnings

Both agencies added osteonecrosis of the jaw (ONJ) warnings to alendronate labeling in 2005, following a wave of case reports linking bisphosphonate use (primarily intravenous formulations in oncology patients) to jaw necrosis after dental procedures.

FDA Label Language on ONJ

The FDA label states that ONJ has been reported in patients treated with bisphosphonates, "most involving patients treated with intravenous bisphosphonates undergoing dental procedures." It recommends a dental examination with appropriate preventive dentistry prior to treatment with bisphosphonates in patients with concomitant risk factors [2]. The International Task Force on Osteonecrosis of the Jaw estimated the risk of ONJ with oral bisphosphonates at 0.001% to 0.01% for the general population, rising to 0.01% to 0.06% after tooth extraction [8].

EMA SmPC Language on ONJ

The EMA SmPC uses similar but not identical language. It tends to include more detail about the specific dental procedures associated with increased risk (extractions, dental implants, poorly fitting dentures) and references the EudraVigilance case series more directly. Some national SmPCs in the EU also include recommendations for interrupting bisphosphonate therapy before planned invasive dental procedures, a step the FDA label suggests but does not mandate.

Generic Approval and Bioequivalence Standards

Generic alendronate availability differs between the two regulatory systems in timing, process, and substitution rules.

FDA Generic Pathway

The first generic alendronate 70 mg tablet was approved by the FDA in February 2008 under the Abbreviated New Drug Application (ANDA) pathway. The FDA requires demonstration of bioequivalence to the reference listed drug (Fosamax) using pharmacokinetic studies in healthy volunteers. As of 2026, there are more than 15 approved ANDA holders for alendronate products in the FDA's Orange Book. Generic substitution at the pharmacy level is automatic in most US states unless the prescriber writes "dispense as written" [9].

EMA Generic Pathway

In the EU, generic applications for alendronate were filed at the national level, with the first approvals appearing in 2007 (ahead of the US, because Merck's supplementary protection certificate expired earlier in some member states). The EMA's guideline on the investigation of bioequivalence (CPMP/EWP/QWP/1401/98 Rev. 1) sets the same 80% to 125% confidence interval for AUC and Cmax as the FDA. However, generic substitution policies vary by member state. Germany, the Netherlands, and the UK (pre-Brexit) permit automatic substitution. France, Spain, and Italy restrict it to pharmacist-initiated substitution with patient consent.

Post-Market Surveillance Infrastructure

The two agencies use fundamentally different electronic surveillance architectures to monitor alendronate safety signals after approval.

FDA Sentinel System

The FDA Sentinel System, launched in 2008 and fully operational by 2016, queries distributed healthcare data from over 100 million patients across participating health plans and academic medical centers. Sentinel runs active surveillance queries. Rather than waiting for voluntary adverse event reports, the FDA can design and execute epidemiological studies against claims and electronic health record data in near-real time. Sentinel has been used to evaluate the bisphosphonate-AFF association using a distributed cohort design [10].

EMA EudraVigilance

The EMA's EudraVigilance system collects Individual Case Safety Reports (ICSRs) from national competent authorities across the EU. It is primarily a passive surveillance system, relying on spontaneous reports from healthcare professionals, patients, and marketing authorisation holders. The EMA supplements EudraVigilance with periodic safety update reports (PSURs) submitted by the manufacturer and signal detection algorithms that flag disproportionate reporting. The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) provides a registry of post-authorisation studies, but it does not offer the same real-time distributed querying capability as Sentinel.

What This Means for Prescribers

The difference is practical. A prescriber in the US can have greater confidence that emerging safety signals for alendronate will be detected through active electronic surveillance, not just voluntary reporting. A prescriber in the EU relies on a system that, while comprehensive in geographic coverage, depends more heavily on the completeness and timeliness of spontaneous reports. Dr. Robert Adler, former Chief of Endocrinology at the McGuire VA Medical Center, has noted: "Active surveillance systems like Sentinel change the conversation from 'we don't know' to 'we looked and here is what we found,' which is a fundamentally different level of evidence for rare adverse events."

Pediatric and Special Population Requirements

The FDA requires a Pediatric Research Equity Act (PREA) assessment for new drug applications, but alendronate predates PREA (enacted 2003). The FDA label includes a pediatric use section noting that alendronate was studied in pediatric patients with osteogenesis imperfecta (OI), but the results were insufficient to support a pediatric indication. The EMA's Paediatric Regulation (EC No 1901/2006) similarly requires a Paediatric Investigation Plan (PIP) for new applications, but national authorisations for alendronate were grandfathered. Both agencies agree: alendronate is not approved for use in children.

The FDA label includes a dedicated pregnancy section (Section 8.1) warning that bisphosphonates are incorporated into the bone matrix and may be released over weeks to years, creating theoretical risk to a developing fetus. The EMA SmPC Section 4.6 uses similar language, classifying alendronate as contraindicated in pregnancy. Neither agency has human pregnancy registry data for alendronate.

Risk Evaluation and Mitigation Strategies

The FDA did not require a Risk Evaluation and Mitigation Strategy (REMS) for alendronate. The agency determined that the existing label warnings, medication guide, and standard prescribing information were sufficient to communicate the drug's risk profile. This stands in contrast to some other osteoporosis drugs. Denosumab (Prolia), for example, did not receive a formal REMS either, but romosozumab (Evenity) carries a boxed warning for cardiovascular risk that the FDA considered but ultimately did not pair with a REMS.

The EMA equivalent, the Risk Management Plan (RMP), is mandatory for all new marketing authorisations and renewals. The RMP for alendronate includes routine pharmacovigilance activities and identifies AFF and ONJ as important identified risks, with esophageal reactions listed as an important identified risk requiring specific label warnings about administration technique.